Zim laboratories Limited has announced a major corporate development with its board of directors approving a comprehensive share issuance plan. The pharmaceutical company's board has given the green light to issue up to 47,64,497 shares at a fixed price of ₹73.46 per share to Florintree Trinex LLP.

Share Issuance Details

The proposed share issuance represents a significant capital raising exercise for the company. The key parameters of this transaction are outlined below:

Shareholder Approval Process

While the board has approved the share issuance plan, the company must obtain formal shareholder consent before proceeding with the transaction. Zim Laboratories has scheduled a special meeting specifically to address this proposal and secure the necessary approvals from its shareholders.

Corporate Governance Framework

The structured approach adopted by Zim Laboratories demonstrates adherence to proper corporate governance practices. The company is following the established protocol of obtaining board approval first, followed by seeking shareholder consent through a dedicated special meeting. This two-tier approval process ensures transparency and proper oversight of significant corporate transactions.

The substantial nature of this share issuance, involving nearly 48 lakh shares, underscores the importance of obtaining explicit shareholder approval before implementation. The company has provided shareholders with adequate notice by scheduling the meeting well in advance, allowing sufficient time for review and consideration of the proposal.

Zim Laboratories Limited, a pharmaceutical company specializing in novel drug delivery systems, has reported a sequential recovery in its Q2 FY26 performance while navigating through EU-GMP compliance challenges. The company's financial results and strategic initiatives were discussed in detail during their recent earnings conference call.

Financial Highlights

Zim Laboratories posted the following key financial metrics for Q2 FY26:

The company's pharmaceutical segment, contributing 83% of total revenue at INR 732.00 million, grew by 30.70% quarter-on-quarter. However, the nutraceutical segment, accounting for 17% of revenue, experienced a decline primarily due to softer domestic demand.

EU-GMP Remediation Progress

Zim Laboratories is actively working on its EU-GMP remediation and CAPA (Corrective Action and Preventive Action) implementation plan, which remains the company's highest strategic priority. The management has set a target to complete the EU-GMP audit by March 2026, with expectations to resume supplies by Q1 or Q2 of FY27.

Dr. Anwar Daud, Chairman and Managing Director, stated, "We recognize that this certification is critical to unlocking value across our regulated markets. At the same time, we are taking proactive steps to maintain business continuity through alternate measures."

Business Continuity Measures

To ensure uninterrupted supply and maintain business continuity, Zim Laboratories has initiated the following actions:

1. Reviewing orders from emerging markets to broaden the certification base
2. Initiating site transfer projects for key products:
   • Tamsulosin + Dutasteride transfer to a TGA-approved site
   • Dimethyl Fumarate and Azithromycin suspension transfers to EU and MHRA-approved facilities

These strategic moves are expected to have a marginal impact on margins but will reinforce the company's business resilience.

Future Outlook

Zim Laboratories maintains a positive outlook for the remainder of FY26:

• The order book for Q3 remains strong, supported by healthy inflow of PMI orders and gradual pickup in domestic demand.
• FY26 revenues are expected to be in line with FY25 levels.
• The management anticipates a recovery in the nutraceutical segment in H2 FY26.
• The company aims to complete its EU-GMP remediation efforts and secure alternate certifications to position itself for sustained growth and value creation once regulatory clearances are reinstated.

Mr. Zulfiquar Kamal, Director of Finance, added, "Based on our current visibility and order book, we are confident in achieving our projected targets for the fiscal year."

Zim Laboratories continues to focus on strengthening its innovative product pipeline and accelerating filing activity across emerging and regulatory markets. The company invested INR 76.00 million in R&D during Q2 FY26, primarily towards new product development, bioequivalence studies, and regulatory filings.

As Zim Laboratories navigates through its current challenges, the management remains optimistic about the company's long-term prospects, emphasizing its commitment to quality, innovation, and strategic expansion in both domestic and international markets.